Neurosense Therapeutics LTD. (NRSN) — SEC Filings
Latest SEC filings for Neurosense Therapeutics LTD.. Recent 6-K filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Neurosense Therapeutics LTD. on SEC EDGAR
Overview
Neurosense Therapeutics LTD. (NRSN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 6, 2026: NeuroSense Therapeutics Ltd. filed a Form 6-K on April 6, 2026, reporting as a foreign private issuer. The filing includes a press release dated April 6, 2026, and related graphic materials. The company's mailing and business address is in Herzliya, Israel.
Sentiment Summary
Across 5 filings, the sentiment breakdown is: 1 bearish, 4 neutral. The dominant filing sentiment for Neurosense Therapeutics LTD. is neutral.
Filing Type Overview
Neurosense Therapeutics LTD. (NRSN) has filed 4 6-K, 1 20-F with the SEC between Mar 2026 to Apr 2026.
Recent Filings (5)
-
NeuroSense Therapeutics Files 6-K Report
— 6-K · Apr 6, 2026 Risk: low
NeuroSense Therapeutics Ltd. filed a Form 6-K on April 6, 2026, reporting as a foreign private issuer. The filing includes a press release dated April 6, 2026, - 6-K Filing — 6-K · Apr 3, 2026
-
NeuroSense Therapeutics Files 6-K Report
— 6-K · Mar 31, 2026 Risk: low
NeuroSense Therapeutics Ltd. filed a Form 6-K on March 31, 2026, reporting its status as a foreign private issuer. The filing includes a press release dated Mar -
NeuroSense Faces 'Going Concern' Warning, Needs Capital for PrimeC
— 20-F · Mar 31, 2026 Risk: high
NeuroSense Therapeutics Ltd. (NRSN) filed its 20-F for the fiscal year ended December 31, 2025, highlighting a critical 'going concern' reference in its financi -
NeuroSense Files Routine 6-K with March 24, 2026 Press Release
— 6-K · Mar 24, 2026
NeuroSense Therapeutics Ltd. filed a 6-K on March 24, 2026, which included a press release dated the same day. This filing, identified by SEC Accession No. 0001
Risk Profile
Risk Assessment: Of NRSN's 3 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 2 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Or Eisenberg
Industry Context
The biotechnology sector, particularly in the development of novel therapeutics for neurological diseases, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like NeuroSense operate in a competitive landscape where success is heavily reliant on clinical trial outcomes and securing substantial funding. The industry faces intense scrutiny regarding drug efficacy, safety, and pricing.
Top Tags
foreign-issuer (3) · regulatory-filing (3) · press-release (3) · Biotechnology (1) · Pharmaceuticals (1) · Going Concern (1) · Clinical Trials (1) · Regulatory Risk (1) · Capital Requirements (1) · ALS Treatment (1)
Key Numbers
- Ordinary Shares Outstanding: 32,557,174 — As of December 31, 2025, indicating the current share count.
- Exchange Rate: NIS 3.19 to $1.00 — Used for U.S. dollar translations of NIS amounts on December 31, 2025.
- Accounting Method Change Date: January 1, 2024 — Date NeuroSense changed from IFRS to U.S. GAAP.
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Neurosense Therapeutics LTD. (NRSN)?
Neurosense Therapeutics LTD. has 5 recent SEC filings from Mar 2026 to Apr 2026, including 4 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NRSN filings?
Across 5 filings, the sentiment breakdown is: 1 bearish, 4 neutral. The dominant sentiment is neutral.
Where can I find Neurosense Therapeutics LTD. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Neurosense Therapeutics LTD. (NRSN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Neurosense Therapeutics LTD.?
Financial highlights for Neurosense Therapeutics LTD. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for NRSN?
The investment thesis for NRSN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Neurosense Therapeutics LTD.?
Key executives identified across Neurosense Therapeutics LTD.'s filings include Or Eisenberg.
What are the main risk factors for Neurosense Therapeutics LTD. stock?
Of NRSN's 3 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Neurosense Therapeutics LTD.?
Forward guidance and predictions for Neurosense Therapeutics LTD. are extracted from SEC filings as they are enriched.